PMID: 25762629Mar 13, 2015Paper

Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma

Oncotarget
Sang-Hyun LeeJeong-Ki Min

Abstract

Endostatin is an endogenous angiogenesis inhibitor that exhibits potential anti-tumor efficacy in various preclinical animal models. However, its relatively short in vivo half-life and the long-term, frequent administration of high doses limit its widespread clinical use. In this study, we evaluated whether a fusion protein of murine endostatin (mEndo) to a humanized antibody against tumor-associated glycoprotein 72 (TAG-72), which is highly expressed in several human tumor tissues including colon cancer, can extend the serum half-life and improve the anti-tumor efficacy of endostatin by targeted delivery to the tumor mass. The fusion protein (3E8-mEndo) and mEndo showed improved anti-angiogenic activity in vitro and in vivo, predominantly by interfering with pro-angiogenic signaling triggered by vascular endothelial growth factor (VEGF). Moreover, in mice treated with 3E8-mEndo, we observed a markedly prolonged serum half-life and significantly inhibited tumor growth. The improved anti-tumor activity of 3E8-mEndo can be partially explained by increased local concentration in the tumor mass due to targeted delivery of 3E8-mEndo to implanted colon tumors. Collectively, our data clearly indicate that tumor-targeting antibody fusi...Continue Reading

References

May 27, 1999·Seminars in Cancer Biology·T Veikkola, K Alitalo
May 15, 2001·American Journal of Physiology. Cell Physiology·I Zachary
Jan 30, 2002·The Journal of Biological Chemistry·Jun-ichi HanaiVikas P Sukhatme
Mar 22, 2002·Nature Reviews. Cancer·P Carter
May 25, 2002·The Journal of Biological Chemistry·Young-Mi KimYoung-Guen Kwon
Jul 31, 2002·The Journal of Cell Biology·Jun-ichi HanaiSergei Sokol
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph P EderDonald W Kufe
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstJames L Abbruzzese
May 12, 2004·Nature Reviews. Drug Discovery·Napoleone FerraraWilliam Novotny
Jan 18, 2006·Annual Review of Medicine·Judah Folkman
Jan 21, 2006·Nature Reviews. Drug Discovery·David SchramaJürgen C Becker
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeCharles S Fuchs
Mar 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tong-Young LeeKashi Javaherian
Mar 12, 2011·Molecular Cancer Therapeutics·Seung-Uon ShinJoseph D Rosenblatt
Jun 30, 2011·The Biochemical Journal·Sina KochLena Claesson-Welsh

❮ Previous
Next ❯

Citations

Feb 13, 2016·Frontiers in Pharmacology·Sylvie Ricard-Blum, Sylvain D Vallet
Feb 1, 2018·Oncotarget·Weiyang LouWeimin Fan
Dec 15, 2015·Biochemical and Biophysical Research Communications·Taek-Keun KimSukmook Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
Yu-mei FengQing-jun Ma
Seikagaku. The Journal of Japanese Biochemical Society
Kota TamadaToru Takumi
Annals of Oncology : Official Journal of the European Society for Medical Oncology
M YamagataM Omata
© 2021 Meta ULC. All rights reserved